Updated June 2026 · USPTO PatentsView
When Does Verzenio Patent Expire?
Verzenio is protected by 1 US patent in the USPTO records tracked here. The earliest patent expires on Sep 28, 2031 (5.2 years from now), opening the door to potential generic or biosimilar competition for that specific composition. Full portfolio protection extends to Sep 28, 2031. Overall Patent Strength Score: 58/100 (Grade C, "moderate").
Verzenio Patent Snapshot
| Total US Patents | 1 |
| Earliest Patent Expiration | Sep 28, 2031 |
| Latest Patent Expiration | Sep 28, 2031 |
| Years Until First Expiry | 5.2 yr |
| Patent Holder | Eli Lilly and Company |
| Generic Name | abemaciclib |
| Patent Strength Score | C58/100 |
When the Verzenio Patent Cliff Hits
Verzenio still has substantial patent life remaining. The earliest expiration is 2031 — 5.2 years out — and the full portfolio runs to 2031. That is comfortably outside the standard window for ANDA filings, but pre-approved biosimilar developers often begin clinical equivalence work 6 to 8 years before composition expiry.
Because Verzenio's earliest patent expiry is more than three years out, generic competition is not imminent. ANDA filings can occur as early as four years after NDA approval (the so-called "5-year exclusivity wall"), but actual market entry is gated by the latest unexpired patent. For clinicians and payers, the planning horizon for generic substitution on Verzenio is 2031 at the earliest.
For the authoritative listing of patents tied to a specific drug — the patents an ANDA filer is legally required to address under 21 USC § 355(j) — consult the FDA Orange Book. Underlying utility patent data on this page is sourced from USPTO PatentsView, the federal government's free public patent API.
Inside the Verzenio Patent Portfolio
Verzenio is protected by a single US patent in the records aggregated here. A one-patent posture is unusual for a commercially significant drug — most blockbusters layer composition, formulation, dosing, and method-of-use patents. A solitary patent typically signals either an early-stage asset, a niche indication, or a portfolio where secondary patents have already lapsed.
All 1 patents in the Verzenio portfolio are assigned to Eli Lilly and Company, indicating consolidated ownership. Single-assignee portfolios are simpler to litigate and easier to license — generic challengers face one negotiating counterparty, and any settlement or pay-for-delay arrangement involves only that holder.
The Verzenio portfolio scores 58/100 (Grade C, "moderate") on the PatentCliff Strength index. The strongest signal is claims breadth (100/100), and the weakest is portfolio size (12/100). The four factors are weighted by how well they predict real-world resilience to generic challenge: portfolio size 30%, claims breadth 25%, time remaining 25%, and technology diversity 20%.
Earliest Patents in the Portfolio
| Patent # | Title | Expires | Years Left |
|---|---|---|---|
| 7855211 | Drug substance & product patent | 2031 | 5.3 |
Verzenio vs Other Branded Drugs
Verzenio's 1-patent portfolio is 88% smaller than the average drug tracked here (8 patents) — lighter-than-typical lifecycle protection. Among the 40 drugs in this database, Verzenio ranks #20 by patent count. For broader context, the earliest expiration in the data set is Ozempic (2026) and the longest-protected drug is Mounjaro (latest expiry 2041).
Expiration Timeline
Looking at the 1 dated patents in the portfolio, the largest cluster (1 patent) falls in the "2–5 years (2029–2031)" bucket. That distribution matters because generic entry is gated by the latest unexpired blocking patent, not the earliest — even one late-expiring formulation patent can delay biosimilar launch by years if it survives a Paragraph IV challenge.
The 20-year patent term in the United States runs from the earliest non-provisional filing date, not the grant date. That means a patent granted in 2015 from a 2010 filing has only 15 years of life left at grant — a feature of US patent law that creates the layered "cliff" pattern visible in most branded drug portfolios. Patent Term Extension under 35 USC § 156 can add up to 5 years for time lost to FDA review, and pediatric exclusivity can add 6 months on top.
How the Patent Strength Score Is Calculated
The PatentCliff Strength Score combines four signals from USPTO data into a single 0-100 grade. Portfolio size (30%) measures the number of patents covering the drug — a proxy for litigation depth and the count of independent challenges a generic must clear. Claims breadth (25%) is the average number of claims per patent, an indicator of how broadly each patent attempts to cover the underlying invention. Time remaining (25%) measures average years until expiration across the portfolio. Technology diversity (20%) measures the number of distinct CPC (Cooperative Patent Classification) classes the portfolio touches — diverse portfolios are harder to design around. Read the full PatentCliff methodology, including how scores compare to citation-weighted academic measures.
Related Questions About Verzenio
Sources: Patent records — USPTO PatentsView API (public domain). Drug-to-patent mapping cross-referenced against the FDA Orange Book. Expiration dates calculated as application date plus 20 years per 35 USC § 154.
Cite as: "PatentCliff, June 2026 reading. Source: USPTO PatentsView." Last updated 2026-06-24.
The data source behind this answer is the FDA Orange Book and USPTO patent records. Every figure on the page traces back to that source; the methodology page describes the inputs and the refresh cadence in full detail.
A practical caveat: the headline answer above reflects the most recent the FDA Orange Book and USPTO patent records vintage; underlying data is often revised for months after first publication, and the right reference for any specific decision is whichever vintage is current at the time of the decision. The as-of date is stamped on every page.